Acción GBSX MARIZYME, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Marizyme, Inc.

Acciones

GBSX

US5703721028

Mercado cerrado - OTC Markets
Otros sitios de cotización
 20:20:59 20/06/2024 		Varia. Cinco días. Varia. 1 de enero.
0,0541 USD -41,83 % Gráfico intradía de Marizyme, Inc. -.--% -45,95 %
28/05 Marizyme, Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024 CI
13/05 Marizyme, Inc. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Marizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Marizyme, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Marizyme : Secures FDA 510(k) Clearance for Controlled Room Temperature storage DuraGraft® - Form 8-K
Marizyme, Inc. Secures FDA 510(k) Clearance for Controlled Room Temperature Storage DuraGraft
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
Marizyme, Inc. Announces Resignation of Julie Kampf from the Board of Directors
Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Marizyme CEO Delivers Business Update
Marizyme CEO Delivers Business Update
OTC Active Stocks Watchlist (EPAZ, MRZM, GCEI, TMGI)
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™
Marizyme, Inc. Announces FDA Clearance for Product, Duragraft
Marizyme, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
MARIZYME, INC. : Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
Marizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Marizyme, Inc. announced a financing transaction
MARIZYME INC : Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products
Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products
Marizyme, Inc. Announces IP Developments for DuraGraft and its Pipeline of Products
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción GBSX
  4. Noticias Marizyme, Inc.
  5. Otros idiomas